AR065622A1 - Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona - Google Patents
Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- onaInfo
- Publication number
- AR065622A1 AR065622A1 ARP080100930A ARP080100930A AR065622A1 AR 065622 A1 AR065622 A1 AR 065622A1 AR P080100930 A ARP080100930 A AR P080100930A AR P080100930 A ARP080100930 A AR P080100930A AR 065622 A1 AR065622 A1 AR 065622A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- fluorine
- diseases
- alkyl substituted
- prevention
- Prior art date
Links
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000011737 fluorine Chemical group 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 102000006239 metabotropic receptors Human genes 0.000 abstract 1
- 108020004083 metabotropic receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Se incluyen los compuestos, las composiciones farmacéuticas y al uso de los compuestos para preparar medicamentos, los cuales son utiles para el tratamiento o prevencion de trastornos neurologicos y psiquiátricos asociados con una disfuncion delglutamato y de enfermedades en las cuales se encuentra involucrado el subtipo mGluR2 de receptores metabotropicos. En particular, dichas enfermedades consisten en trastornos del SNC seleccionados del grupo de ansiedad, esquizofrenia, migrana,depresion, y epilepsia. La presente también se dirige a composiciones farmacéuticas y a procesos para preparar dichos compuestos y dichas composiciones, así como también al uso de dichos compuestos para la prevencion y el tratamiento de dichasenfermedades en las cuales se encuentra involucrado el mGluR2. Reivindicacion 1: Un compuesto de la formula (1) incluyendo cualquier forma estereoquímicamente isomérica del mismo, en donde R1 es alquilo C4-6, o alquilo C1-3 sustituido concicloalquilo C3-7; R2 es hidrogeno; fluor; alquilo C1-4 sustituido con hidroxilo; alquilo C1-4 sustituido con fluor; o alquiloxi C1-4 sustituido con fluor; o una sal farmacéuticamente aceptable del mismo o un solvato del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07103654 | 2007-03-07 | ||
PCT/EP2007/052442 WO2007104783A2 (en) | 2006-03-15 | 2007-03-15 | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators |
EP07116401 | 2007-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065622A1 true AR065622A1 (es) | 2009-06-17 |
Family
ID=39430637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100930A AR065622A1 (es) | 2007-03-07 | 2008-03-06 | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100063092A1 (es) |
EP (1) | EP2134701A1 (es) |
JP (1) | JP2010520263A (es) |
KR (1) | KR20090125813A (es) |
CN (1) | CN101679349A (es) |
AR (1) | AR065622A1 (es) |
AU (1) | AU2008223794A1 (es) |
BR (1) | BRPI0808666A2 (es) |
CA (1) | CA2680120A1 (es) |
EA (1) | EA017280B1 (es) |
IL (1) | IL200328A0 (es) |
MX (1) | MX2009009423A (es) |
TW (1) | TW200900391A (es) |
WO (1) | WO2008107479A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
MY156814A (en) | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
JP5133416B2 (ja) * | 2007-09-14 | 2013-01-30 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1’,3’−二置換−4−フェニル−3,4,5,6−テトラヒドロ−2h,1’h−[1,4’]ビピリジニル−2’−オン |
US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
WO2009062676A2 (en) | 2007-11-14 | 2009-05-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2430031B1 (en) | 2009-05-12 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US8648192B2 (en) | 2010-05-26 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
PT3013813T (pt) | 2013-06-27 | 2019-06-14 | Pfizer | Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
PL3431106T3 (pl) | 2014-01-21 | 2021-06-28 | Janssen Pharmaceutica Nv | Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
CN105153027A (zh) * | 2015-07-21 | 2015-12-16 | 东华大学 | 一种3-氰基-4-羟基-2-吡啶酮类化合物及其制备和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001234420A1 (en) * | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
CA2495756A1 (en) * | 2002-08-26 | 2004-03-04 | Merck & Co., Inc. | Acetophenone potentiators of metabotropic glutamate receptors |
ES2300798T3 (es) * | 2003-04-15 | 2008-06-16 | Astrazeneca Ab | Benzosulfonamidas sustituidas como potenciadores de los receptores de glutamato. |
WO2005080356A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
US20080293684A1 (en) * | 2004-07-30 | 2008-11-27 | Anthony B Pinkerton | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors |
CA2574971A1 (en) * | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) * | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
-
2008
- 2008-03-06 TW TW097107950A patent/TW200900391A/zh unknown
- 2008-03-06 AR ARP080100930A patent/AR065622A1/es not_active Application Discontinuation
- 2008-03-07 US US12/529,632 patent/US20100063092A1/en not_active Abandoned
- 2008-03-07 EP EP08717513A patent/EP2134701A1/en not_active Withdrawn
- 2008-03-07 EA EA200901159A patent/EA017280B1/ru not_active IP Right Cessation
- 2008-03-07 BR BRPI0808666-4A patent/BRPI0808666A2/pt not_active IP Right Cessation
- 2008-03-07 MX MX2009009423A patent/MX2009009423A/es active IP Right Grant
- 2008-03-07 KR KR1020097020925A patent/KR20090125813A/ko not_active Application Discontinuation
- 2008-03-07 AU AU2008223794A patent/AU2008223794A1/en not_active Abandoned
- 2008-03-07 WO PCT/EP2008/052766 patent/WO2008107479A1/en active Application Filing
- 2008-03-07 CA CA002680120A patent/CA2680120A1/en not_active Abandoned
- 2008-03-07 CN CN200880007307A patent/CN101679349A/zh active Pending
- 2008-03-07 JP JP2009552214A patent/JP2010520263A/ja active Pending
-
2009
- 2009-08-11 IL IL200328A patent/IL200328A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2134701A1 (en) | 2009-12-23 |
IL200328A0 (en) | 2010-04-29 |
CN101679349A (zh) | 2010-03-24 |
BRPI0808666A2 (pt) | 2014-08-26 |
US20100063092A1 (en) | 2010-03-11 |
KR20090125813A (ko) | 2009-12-07 |
TW200900391A (en) | 2009-01-01 |
MX2009009423A (es) | 2010-02-09 |
JP2010520263A (ja) | 2010-06-10 |
CA2680120A1 (en) | 2008-09-12 |
AU2008223794A1 (en) | 2008-09-12 |
EA017280B1 (ru) | 2012-11-30 |
EA200901159A1 (ru) | 2010-04-30 |
WO2008107479A1 (en) | 2008-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
AR068510A1 (es) | Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central. | |
CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
AR065654A1 (es) | 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona derivados,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos,y usos para prevenir o tratar trastornos neurologicos y psiquiatricos. | |
ECSP10010209A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
AR068512A1 (es) | Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
CL2011002839A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos positivos de receptores mglur2; composición farmacéutica y su proceso de preparacion; combinación farmaceutica; y su uso en el tratamiento o prevencion de un trastorno del sistema nervioso central tal como ansiedad y esquizofrenia, entre otros. | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
AR077999A1 (es) | Antagonistas de pirimidin y triazin-hepcidina | |
RU2014121205A (ru) | Производные азолов | |
AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
ECSP088257A (es) | Derivados de amida | |
CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
AR074325A1 (es) | Compuesto de 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazole, composicion y medicamento que lo comprende y uso y metodo de sintesis del compuesto | |
AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
AR054109A1 (es) | Derivados de 2-metil-4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de la infertilidad | |
AR064198A1 (es) | Piperidinilamino piridazinas como antagonistas del receptor de dopamina 2 de rapida disociacion. procesos de obtencion y composiciones farmaceuticas | |
AR062124A1 (es) | Moduladores de la actividad del receptor de quimiocina formas cristalinas y procesos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |